#India #Mumbai #Piramal Pharma #bioconjugates #IntoCell

Piramal Pharma Solutions and IntoCell: A Strategic Partnership to Advance Bioconjugate Technology

Piramal Pharma Solutions, a global player in contract development and manufacturing (CDMO), has recently formalized a partnership with IntoCell, a leading South Korean biotechnology company. This collaboration aims to bolster Piramal's bioconjugate capabilities, focusing particularly on antibody-drug conjugates (ADCs). By leveraging IntoCell's proprietary drug-linker technologies and its extensive 20 years of experience, Piramal is set to enhance its competitive edge in the bioconjugate market.

The Scope of Collaboration

The partnership is cemented through a Memorandum of Understanding (MOU), which allows for exploration of potential collaborative opportunities in ADC development. IntoCell, recognized for its innovative linker and payload technologies, will investigate licensing options for its drug-linker platforms to Piramal's clientele. In return, Piramal commits to providing comprehensive contract research, development, and manufacturing services for bioconjugates, including ADCs, to IntoCell.

This strategic alignment not only enhances the existing strengths of Piramal in payload-linker technologies but also streamlines the development process. Customers will benefit from a wider selection of payload-linkers and expedited development timelines for bioconjugates.

Enhancing ADCelerate™

Central to this partnership is ADCelerate™, Piramal’s accelerated approach to the development and manufacturing of ADCs. By harnessing the resources and expertise available at IntoCell, Piramal seeks to optimize the pathway from concept to clinical application.

Tae Kyo Park, the CEO of IntoCell, expressed enthusiasm for the collaboration, emphasizing the potential for joint success through the blending of the two companies' expertise. "Together, we aim to redefine the future of ADCs and enhance patient outcomes globally," said Peter DeYoung, CEO of Piramal Global Pharma.

Piramal's Core Competence

Piramal Pharma Solutions offers an end-to-end solution encompassing drug development and manufacturing throughout the entire lifecycle of pharmaceuticals. The company operates through a globally integrated network that spans North America, Europe, and Asia. Services provided include drug research, process development, clinical trial supplies, commercial API delivery, and finished dosage forms. Moreover, Piramal specializes in the development and manufacturing of high-potency APIs, sterile filling, and biologics, including vaccines and gene therapies.

By leveraging the strengths of this partnership, Piramal aims to ensure that it can continue to meet the growing demands of the bioconjugate market, ultimately delivering better results for patients.

To summarize, the alliance between Piramal Pharma Solutions and IntoCell marks a significant step in the evolution of bioconjugate technology. With an enhanced portfolio of drug-linker and payload technologies, the two companies are poised to lead innovations in the ADC sector, thereby impacting the pharmaceutical landscape positively.

For additional insights, visit the Piramal Pharma Solutions website or view their profiles on LinkedIn and Facebook.